However, the available (steroidal) MR antagonists (MRAs) spironolactone, and its sole successor eplerenone, suffer from substantial drawbacks that limit their clinical use, e.g. hyperkalemia especially in patients with severe chronic kidney disease (CKD) [8]. Here, NR3C2 is linked to chronic kidney disease.